AVCRF: AI 评分 57/100 — AI 分析 (4月 2026)

Avricore Health Inc. operates in the health data and point-of-care technologies sector, offering the HealthTab platform for pharmacies. Strategic partnerships with Shoppers Drug Marts and Abbott drive its market presence in Canada.

Key Facts: AI Score: 57/100 Sector: Healthcare

公司概况

概要：

Avricore Health Inc. provides the HealthTab point-of-care testing platform, enabling lab-accurate diagnostics in pharmacies. The company focuses on health data and technology solutions within the Canadian healthcare market, leveraging partnerships with major players like Shoppers Drug Marts and Abbott to expand its reach and service offerings.

AVCRF是做什么的？

Avricore Health Inc., originally founded as Vanc Pharmaceuticals Inc. in 1996 and rebranded in October 2018, is a Canadian company focused on point-of-care technologies and health data solutions. Headquartered in Vancouver, the company's primary offering is HealthTab, a platform designed to provide lab-accurate diagnostic testing within pharmacy settings. This technology allows for convenient and accessible health monitoring, catering to the growing demand for decentralized healthcare services. Through HealthTab, Avricore Health aims to bridge the gap between traditional lab testing and immediate patient needs, offering a range of diagnostic tests directly in pharmacies. The company has established strategic partnerships with Shoppers Drug Marts and Abbott, enhancing its market reach and credibility within the Canadian healthcare landscape. These collaborations enable Avricore Health to integrate its technology into established pharmacy networks, providing a seamless experience for both healthcare providers and patients. Avricore Health continues to innovate and expand its HealthTab platform, focusing on delivering accessible and reliable health data solutions to improve patient outcomes and streamline healthcare delivery.

AVCRF的投资论点是什么？

Avricore Health Inc. presents a focused investment opportunity within the point-of-care diagnostics market in Canada. The company's HealthTab platform, offering lab-accurate testing in pharmacies, addresses the increasing demand for accessible and convenient healthcare solutions. Strategic partnerships with Shoppers Drug Marts and Abbott provide a strong foundation for market penetration and expansion. However, the company's negative P/E ratio of -4.35 and a profit margin of -84.7% indicate significant challenges in achieving profitability. The low beta of 0.31 suggests relatively low volatility compared to the market. Key value drivers include expanding the HealthTab platform's test menu, securing additional pharmacy partnerships, and leveraging health data for personalized healthcare solutions. The path to profitability and sustainable growth remains a critical factor for investors to consider.

AVCRF在哪个行业运营？

Avricore Health Inc. operates within the rapidly evolving medical diagnostics and research industry, driven by increasing demand for point-of-care testing and personalized healthcare solutions. The market is characterized by technological advancements, regulatory changes, and shifting consumer preferences towards accessible and convenient healthcare services. Competitors include companies like AVTBF (Avant Technologies Inc.), BBRRF (Biome Grow Inc.), BUDZ (BUDZ, INC.), ICBU (ICB International Consolidated Business Corp), and IDXG (IDEXX Laboratories, Inc.), each offering various diagnostic solutions and technologies. Avricore Health's focus on pharmacy-based testing positions it within a niche segment of the market, leveraging the accessibility and convenience of pharmacies to deliver diagnostic services.

Medical - Diagnostics & Research

Healthcare

AVCRF有哪些增长机遇？

Expanding the HealthTab platform's test menu: Avricore Health can drive growth by continually expanding the range of diagnostic tests available on the HealthTab platform. This includes incorporating tests for chronic diseases, infectious diseases, and other common health conditions. The point-of-care diagnostics market is projected to reach $40 billion by 2028, offering a significant opportunity for Avricore Health to capture market share by offering a comprehensive testing solution. Timeline: Ongoing.
Securing additional pharmacy partnerships: Building on existing partnerships with Shoppers Drug Marts, Avricore Health can pursue collaborations with other pharmacy chains and independent pharmacies across Canada. Expanding the network of HealthTab-enabled pharmacies will increase accessibility and drive revenue growth. The Canadian pharmacy market is estimated at $35 billion annually, providing a large potential customer base for Avricore Health's services. Timeline: Ongoing.
Leveraging health data for personalized healthcare solutions: Avricore Health can leverage the data collected through the HealthTab platform to develop personalized healthcare solutions and services. This includes offering tailored health recommendations, disease management programs, and remote patient monitoring services. The personalized medicine market is expected to reach $2.4 billion by 2027, presenting a significant growth opportunity for Avricore Health. Timeline: 2027.
Geographic expansion beyond Canada: While currently focused on the Canadian market, Avricore Health can explore opportunities to expand its operations to other countries with similar healthcare systems and market dynamics. This could include entering the US market or partnering with international pharmacy chains to deploy the HealthTab platform globally. The global point-of-care diagnostics market is projected to reach $50 billion by 2029, offering a vast potential market for Avricore Health's expansion. Timeline: 2029.
Integrating with telehealth platforms: Avricore Health can integrate the HealthTab platform with telehealth platforms to provide remote diagnostic testing and virtual healthcare services. This would enable patients to access diagnostic testing from the comfort of their homes and receive virtual consultations with healthcare providers. The telehealth market is expected to reach $55 billion by 2027, creating a synergistic opportunity for Avricore Health to expand its service offerings. Timeline: 2027.

Market Cap of $0.01B indicates a small-cap company with potential for growth but also higher risk.
P/E Ratio of -4.35 reflects the company's current lack of profitability.
Gross Margin of 43.4% suggests a viable business model with potential for profitability if costs are managed effectively.
Beta of 0.31 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.
Strategic partnerships with Shoppers Drug Marts and Abbott provide a strong foundation for market access and credibility.

AVCRF提供哪些产品和服务？

Provides the HealthTab platform for lab-accurate point-of-care testing.
Enables diagnostic testing within pharmacy settings.
Offers a range of diagnostic tests directly in pharmacies.
Bridges the gap between traditional lab testing and immediate patient needs.
Integrates technology into established pharmacy networks.
Delivers accessible and reliable health data solutions.

AVCRF如何赚钱？

Generates revenue through the sale and licensing of the HealthTab platform.
Partners with pharmacies to offer diagnostic testing services.
Collects and analyzes health data to provide personalized healthcare solutions.

Pharmacies seeking to offer point-of-care diagnostic testing.
Patients seeking convenient and accessible health monitoring.
Healthcare providers seeking to improve patient outcomes.

Strategic partnerships with Shoppers Drug Marts and Abbott provide a competitive advantage.
Proprietary HealthTab platform offers a unique point-of-care testing solution.
Focus on health data and personalized healthcare solutions creates differentiation.

什么因素可能推动AVCRF股价上涨？

Ongoing: Expansion of the HealthTab platform's test menu to include additional diagnostic tests.
Ongoing: Securing new partnerships with pharmacy chains and independent pharmacies across Canada.
Upcoming: Potential integration of the HealthTab platform with telehealth platforms by 2027.
Upcoming: Possible geographic expansion beyond Canada by 2029.
Ongoing: Leveraging health data for personalized healthcare solutions and services.

AVCRF的主要风险是什么？

Potential: Competition from established diagnostic companies with greater resources and market share.
Potential: Regulatory changes in the healthcare industry that could impact the adoption of point-of-care testing.
Potential: Technological advancements that could render the HealthTab platform obsolete.
Ongoing: Limited financial resources and profitability challenges.
Ongoing: Dependence on key partnerships with Shoppers Drug Marts and Abbott.

AVCRF的核心优势是什么？

Proprietary HealthTab platform.
Strategic partnerships with Shoppers Drug Marts and Abbott.
Focus on point-of-care testing.
Experienced management team.

AVCRF的劣势是什么？

Negative P/E ratio and low profitability.
Limited market presence outside of Canada.
Dependence on key partnerships.
Limited financial resources.

AVCRF有哪些机遇？

Expanding the HealthTab platform's test menu.
Securing additional pharmacy partnerships.
Leveraging health data for personalized healthcare solutions.
Geographic expansion beyond Canada.

AVCRF面临哪些威胁？

Competition from established diagnostic companies.
Regulatory changes in the healthcare industry.
Technological advancements that could render the HealthTab platform obsolete.
Economic downturn that could reduce healthcare spending.

AVCRF的竞争对手是谁？

Avant Technologies Inc. — Offers technology solutions for various industries. — (AVTBF)
Biome Grow Inc. — Focuses on cannabis cultivation and processing. — (BBRRF)
BUDZ, INC. — Operates in the cannabis industry. — (BUDZ)
ICB International Consolidated Business Corp — Provides business consulting and investment services. — (ICBU)
IDEXX Laboratories, Inc. — Offers diagnostic and information technology-based solutions for animal health. — (IDXG)

Key Metrics

MoonshotScore: 57/100

Company Profile

CEO: Rodger Seccombe
Headquarters: Vancouver, CA
Founded: 2009

AI Insight

AI analysis pending for AVCRF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Avricore Health Inc. do?

Avricore Health Inc. is a Canadian healthcare technology company that provides the HealthTab platform, a lab-accurate point-of-care testing solution for pharmacies. HealthTab enables pharmacies to offer a range of diagnostic tests directly to patients, bridging the gap between traditional lab testing and immediate healthcare needs. The company generates revenue through the sale and licensing of the HealthTab platform and by partnering with pharmacies to offer diagnostic testing services. Avricore Health aims to improve patient outcomes and streamline healthcare delivery by providing accessible and reliable health data solutions.

What do analysts say about AVCRF stock?

As of 2026-03-17, formal analyst ratings for AVCRF are not widely available, likely due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors. Key valuation metrics include the negative P/E ratio, which reflects current unprofitability, and the gross margin of 43.4%, which indicates the potential for profitability if costs are managed effectively. Growth considerations include expanding the HealthTab platform's test menu and securing additional pharmacy partnerships. The lack of analyst coverage underscores the importance of independent research and a cautious approach to investing in AVCRF.

What are the main risks for AVCRF?

The main risks for Avricore Health Inc. include competition from established diagnostic companies, regulatory changes in the healthcare industry, and technological advancements that could render the HealthTab platform obsolete. The company also faces financial risks due to its limited resources and profitability challenges. Dependence on key partnerships with Shoppers Drug Marts and Abbott is another significant risk factor. Furthermore, as an OTC-listed company, AVCRF is subject to greater price volatility and liquidity constraints compared to companies listed on major exchanges. Investors should carefully consider these risks before investing in AVCRF.